SELLAS Life Sciences opened lower at $8.16, compared with its previous close of $8.42. In the last trading session, the stock traded between $8.00 and $8.41. It showed a downward intraday trend.
An investment of $100 made 5 years ago in SELLAS Life Sciences is now worth
$ 91.03
Resulting in a loss of
$ 8.97 (8.97%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.40 (-4.75%)
Day High
$8.41
Day Low
$8.00
Day Open
$8.16
Prev Close
$8.42
Volume
31,18,915
1W Return
-12.37%
1M Return
-32.79%
3M Return
-27.14%
6M Return
52.76%
1Y Return
431.13%
Market Cap ($ Mn)
1,620
PE Ratio
-
PB Ratio
19.35
PEG Ratio
-
ROE
-74.67%
ROCE
-78.00%
EPS (TTM)
$-0.05
1 Week
-12.37%
1 Month
-32.79%
3 Months
-27.14%
6 Months
52.76%
9 Months
118.53%
Sellas Life Sciences to present Phase 2 AML data at ASH meeting
Sellas Life Sciences to present Phase 2 data for SLS009 at ASH meeting. Monocytic AML patients achieved 54% ORR and 5.8 months median OS. TP53-mutated AML patients recorded 57% ORR and 8.8 months median OS. Survival rates exceed historical benchmarks of approximately 2.5 months.
8 days agoSELLAS SLS009 shows 6x higher apoptosis than daraxonrasib in resistant PDAC
SLS009 induced 17.9% apoptosis in resistant PDAC models, six-fold higher than daraxonrasib's 2.8%. Combination of SLS009 and daraxonrasib increased apoptosis to 36.5% and necrosis to 30.6%. Data presented at AACR Conference on Pancreatic Cancer in San Diego on September 25, 2026. Study used patient-derived organoid models in collaboration with University of Wisconsin–Madison.
1mo agoPomerantz probes SELLAS Life Sciences over delayed trial data
Pomerantz LLP investigates SELLAS Life Sciences for alleged securities fraud. Probe concerns delayed release of phase 3 GPS trial results after 80th patient death. SLS shares fell $2.00, or 13.15%, to close at $13.21 on August 28, 2026. Investors advised to contact Danielle Peyton at Pomerantz LLP for class action info.
1mo agoSellas Life Sciences to present SLS009 pancreatic cancer data at AACR
Three abstracts on SLS009 accepted for poster presentation at AACR conference. Data covers preclinical activity in KRAS mutant organoid models of PDAC. Studies conducted with University of Wisconsin School of Medicine and Public Health. Conference scheduled for September 25–28, 2026, in San Diego.
2mo agoSellas Life Sciences faces investor probe over phase 3 trial data delay
Pomerantz LLP investigates Sellas Life Sciences for potential securities fraud. Probe triggered by failure to release phase 3 trial results after hitting death milestone. Sellas stock fell 13.15% to $13.21 per share on August 28, 2026. Investors are advised to contact the firm to discuss potential claims.
2mo agoBMF Capital targets SELLAS Life Sciences, cites $3 billion overvaluation
BMF Capital discloses short position in SELLAS Life Sciences, citing dangerous overvaluation. Firm estimates 74% downside to $3.50 per share if Phase 3 REGAL trial fails. Report criticizes trial design, noting comparison group includes only 10 patients. Stock fell 13.15% to $13.21 on Friday despite 621.86% gain over past year. Maxim Group maintains buy rating with $10 price target.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in SELLAS Life Sciences is now worth
$ 91.03
Resulting in a loss of
$ 8.97 (8.97%)
Note: Past profits do not guarantee future returns.
